These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30647822)

  • 1. Economic Burden of Adverse Events Associated with Immunotherapy and Targeted Therapy for Metastatic Melanoma in the Elderly.
    Ghate SR; Li Z; Tang J; Nakasato AR
    Am Health Drug Benefits; 2018 Oct; 11(7):334-343. PubMed ID: 30647822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic burden associated with adverse events in patients with metastatic melanoma.
    Arondekar B; Curkendall S; Monberg M; Mirakhur B; Oglesby AK; Lenhart GM; Meyer N
    J Manag Care Spec Pharm; 2015 Feb; 21(2):158-64. PubMed ID: 25615005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries.
    Vouk K; Benter U; Amonkar MM; Marocco A; Stapelkamp C; Pfersch S; Benjamin L
    J Med Econ; 2016 Sep; 19(9):900-12. PubMed ID: 27123564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic Burden of Toxicities Associated with Treating Metastatic Melanoma in the United States.
    Bilir SP; Ma Q; Zhao Z; Wehler E; Munakata J; Barber B
    Am Health Drug Benefits; 2016 Jun; 9(4):203-13. PubMed ID: 27688833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer.
    Engel-Nitz NM; Johnson MP; Bunner SH; Ryan KJ
    J Manag Care Spec Pharm; 2020 Jun; 26(6):729-740. PubMed ID: 32463768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen deprivation therapy.
    Shah A; Shah R; Kebede N; Mohamed A; Botteman M; Waldeck R; Hussain A
    J Med Econ; 2020 Apr; 23(4):330-346. PubMed ID: 31835965
    [No Abstract]   [Full Text] [Related]  

  • 7. Costs associated with adverse events for systemic therapies in metastatic melanoma.
    Fu AZ; Li Z; Tang J; Mahmood S; Whisman T; Qiu Y
    J Comp Eff Res; 2018 Sep; 7(9):867-879. PubMed ID: 30192155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma.
    Hagiwara M; Hackshaw MD; Oster G
    J Med Econ; 2013 Nov; 16(11):1300-6. PubMed ID: 24004437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study.
    Gullo G; Rubatto M; Fava P; Brizio M; Tonella L; Ribero S; Medri M; Avallone G; Mastorino L; Fierro MT; Stanganelli I; Quaglino P
    Dermatol Ther; 2022 Jun; 35(6):e15492. PubMed ID: 35384181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States.
    Latremouille-Viau D; Chang J; Guerin A; Shi S; Wang E; Yu J; Ngai C
    J Med Econ; 2017 Jan; 20(1):54-62. PubMed ID: 27603498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using a cancer registry to capture signals of adverse events following immune and targeted therapy for melanoma.
    Aguiar JP; Cardoso Borges F; Murteira R; Ramos C; Gouveia E; Passos MJ; Miranda A; da Costa FA
    Int J Clin Pharm; 2018 Aug; 40(4):852-861. PubMed ID: 29860707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs associated with adverse events in patients with metastatic renal cell carcinoma.
    Borker R
    J Med Econ; 2014 Nov; 17(11):792-7. PubMed ID: 25116694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic and health care resource utilization burden of central nervous system metastases in patients with metastatic melanoma.
    Tawbi H; Bartley K; Seetasith A; Kent M; Lee J; Burton E; Haydu L; McKenna E
    J Manag Care Spec Pharm; 2022 Mar; 28(3):342-353. PubMed ID: 35199578
    [No Abstract]   [Full Text] [Related]  

  • 14. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
    Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
    JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An economic evaluation of perioperative adverse events associated with spinal surgery.
    Hellsten EK; Hanbidge MA; Manos AN; Lewis SJ; Massicotte EM; Fehlings MG; Coyte PC; Rampersaud YR
    Spine J; 2013 Jan; 13(1):44-53. PubMed ID: 23384882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy.
    Borghaei H; Yim YM; Guerin A; Pivneva I; Shi S; Gandhi M; Ionescu-Ittu R
    Lung Cancer; 2018 May; 119():112-119. PubMed ID: 29656745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse event-related costs for systemic metastatic breast cancer treatment among female Medicaid beneficiaries.
    Irwin DE; Masaquel A; Johnston S; Barnett B
    J Med Econ; 2016 Nov; 19(11):1027-1033. PubMed ID: 27206801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens.
    Hansen RN; Ramsey SD; Lalla D; Masaquel A; Kamath T; Brammer M; Hurvitz SA; Sullivan SD
    Springerplus; 2014; 3():259. PubMed ID: 24926422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of costs associated with adverse events in patients with cancer.
    Wong W; Yim YM; Kim A; Cloutier M; Gauthier-Loiselle M; Gagnon-Sanschagrin P; Guerin A
    PLoS One; 2018; 13(4):e0196007. PubMed ID: 29652926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acceptability of Drugs in the Treatment of Unresectable/Metastatic BRAF V600-Mutant Melanoma: A Systematic Review and Network Meta-Analysis.
    Hong L; Huang P; Zheng X; Ye X; Zhao H; Wang J; Shao Y
    Front Oncol; 2022; 12():865656. PubMed ID: 35530323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.